Qualigen Therapeutics Inc (QLGN) — Capital Reinvestment Ratio
Latest as of September 2023:
0.27x
Qualigen Therapeutics Inc (QLGN) has a Capital Reinvestment Ratio of 0.27x as of September 2023, meaning it reinvests 0% of its operating cash flow ($929.74K) in capital expenditures ($246.42K). See QLGN cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.27x
Capex / Operating Cash Flow
Operating Cash Flow
$929.74K
USD
Capital Expenditures
$246.42K
USD
Data as of
Sep 2023
Most recent filing
Qualigen Therapeutics Inc Capital Reinvestment Ratio (2019–2019)
This chart tracks Qualigen Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Qualigen Therapeutics Inc (2019–2019)
Year-by-year Capital Reinvestment Ratio for Qualigen Therapeutics Inc from 2019 to 2019. For live market cap and broader valuation context, see Qualigen Therapeutics Inc stock valuation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2019 | 3.39x | $57.33K | $194.48K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow